{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:30:33Z","timestamp":1790116233918,"version":"4.0.1"},"reference-count":27,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Background: Perianal fistulizing Crohn\u2019s disease (CD) is associated with significant morbidity and remains difficult to treat. Although advanced medical therapies are widely used, much of the available evidence derives from heterogeneous fistula populations or luminal CD trials, with limited perianal-specific synthesis and inconsistent outcome definitions. We conducted a systematic review focusing exclusively on perianal-specific clinical, radiologic, and composite outcomes in adults with perianal fistula (PAF) CD. Methods: We performed a systematic review in accordance with PRISMA 2020. Electronic databases were searched from inception through November 2025. We included randomized controlled trials and cohort studies enrolling adults with CD reporting outcomes specific to PAF. Interventions included biologics and small-molecule therapies, compared with placebo or other therapies. Due to substantial heterogeneity in outcome definitions and study designs, a meta-analysis was not performed. Risk of bias was assessed using Risk of Bias 2 (RoB 2) for randomized trials and the Newcastle\u2013Ottawa Scale for observational studies. Results: Seven studies including &gt;1200 participants with PAF-CD met inclusion criteria. Follow-up ranged from 24 weeks to 5 years. Across studies, outcome definitions and assessment modalities varied. Upadacitinib demonstrated significantly higher clinical fistula closure compared with placebo across multiple dose regimens at 52 weeks. In observational comparisons, ustekinumab and vedolizumab were associated with higher clinical closure rates than anti-TNF therapies. However, infliximab demonstrated higher closure rates than adalimumab as a first-line treatment. The definition for radiologic remission was less consistent across studies and often did not parallel clinical outcomes. Composite clinical\u2013radiologic remission and response were reported in a limited number of studies, with filgotinib showing higher composite outcomes in comparison to placebo in a phase 2 trial. Surgical interventions, relapse outcomes, biomarkers [C-reactive protein (CRP)\/fecal calprotectin (FCP)], and patient-reported outcomes were variably reported and not consistently significant across comparisons. Conclusions: Evidence for advanced therapies in PAF CD remains limited by heterogeneity in endpoint definitions, subjectivity in clinical observation, inconsistent radiologic reporting, and reliance on subgroup or observational comparisons. While anti-TNF therapy remains the most established option in guidelines, emerging data suggest significant benefits with ustekinumab, vedolizumab, and JAK inhibitors in selected patients. There is a need for PAF-specific, adequately powered randomized trials using standardized composite clinical and radiologic endpoints.<\/jats:p>","DOI":"10.3390\/ph19030417","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T15:01:07Z","timestamp":1772636467000},"page":"417","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Advanced Medical Therapies for Perianal Fistulizing Crohn\u2019s Disease: A Systematic Review of Clinical, Radiological, Surgical, and Composite Outcomes"],"prefix":"10.3390","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-6286-3855","authenticated-orcid":false,"given":"Fares","family":"Jamal","sequence":"first","affiliation":[{"name":"Department of Hematology & Oncology, Mayo Clinic, Phoenix, AZ 85054, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tayo","family":"Segun-Omosehin","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor","family":"Viggiano","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Mayo Clinic, Phoenix, AZ 85054, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamza","family":"Khan","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Northern Arizona Healthcare, Verde Valley, AZ 86326, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5714-2130","authenticated-orcid":false,"given":"Alejandro J.","family":"Gonzalez","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Mayo Clinic, Phoenix, AZ 85054, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoff","family":"Thomas","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Mayo Clinic, Phoenix, AZ 85054, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Elmasry","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Mayo Clinic, Phoenix, AZ 85054, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6440-6064","authenticated-orcid":false,"given":"Talha A.","family":"Malik","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology & Hepatology, Mayo Clinic, Phoenix, AZ 85054, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.14309\/ajg.0000000000002326","article-title":"Management of Perianal Crohn\u2019s Disease","volume":"118","author":"Parian","year":"2023","journal-title":"Am. J. Gastroenterol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Shlomo, Y., Lital, B., Ofra, C., Yehudit, C., Rosi, G., Tali, M., and Ariella, B.S. (2026). Effect of Perianal Disease on Quality of Life, Fecal Incontinence, and Sexual Function in Patients with Crohn\u2019s Disease. Dig. Dis. Sci.","DOI":"10.1007\/s10620-026-09766-0"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.14309\/ajg.0000000000003465","article-title":"ACG Clinical Guideline: Management of Crohn\u2019s Disease in Adults","volume":"120","author":"Lichtenstein","year":"2025","journal-title":"Am. J. Gastroenterol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1053\/j.gastro.2021.04.023","article-title":"AGA Technical Review on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn\u2019s Disease","volume":"160","author":"Singh","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1053\/j.gastro.2021.04.022","article-title":"AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn\u2019s Disease","volume":"160","author":"Feuerstein","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/nrgastro.2017.104","article-title":"Perianal fistulizing Crohn\u2019s disease: Pathogenesis, diagnosis and therapy","volume":"14","author":"Panes","year":"2017","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.cgh.2025.02.009","article-title":"Defining Radiological Healing in Perianal Fistulizing Crohn\u2019s Disease: A TOpClass Global Expert Delphi Consensus","volume":"24","author":"Anand","year":"2026","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"110611","DOI":"10.3748\/wjg.v31.i34.110611","article-title":"Imaging in perianal fistulising Crohn\u2019s disease: A practical guide for the gastroenterologist","volume":"31","author":"Habeeb","year":"2025","journal-title":"World J. Gastroenterol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1093\/ecco-jcc\/jjab168","article-title":"Fibrosis and MAGNIFI-CD Activity Index at Magnetic Resonance Imaging to Predict Treatment Outcome in Perianal Fistulizing Crohn\u2019s Disease Patients","volume":"16","author":"Bossuyt","year":"2022","journal-title":"J. Crohns Colitis"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1093\/ecco-jcc\/jjab026","article-title":"Endpoints for Perianal Crohn\u2019s Disease Trials: Past, Present and Future","volume":"15","author":"Caron","year":"2021","journal-title":"J. Crohns Colitis"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","article-title":"Infliximab for the treatment of fistulas in patients with Crohn\u2019s disease","volume":"340","author":"Present","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1093\/ibd\/izac103","article-title":"Comparative Efficacy of Biologic Therapies for Inducing Response and Remission in Fistulizing Crohn\u2019s Disease: Systematic Review and Network Meta-Analysis of Randomized Controlled Trials","volume":"29","author":"Shehab","year":"2023","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Reinisch, W., Atreya, R., Rieder, F., Jairath, V., Rimola, J., Peyrin-Biroulet, L., Tozer, P., Buskens, C.J., and Hart, A. (2026). Clinical Trial Endpoints for Perianal Fistulizing Crohn\u2019s Disease. Am. J. Gastroenterol.","DOI":"10.14309\/ajg.0000000000003906"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur. J. Epidemiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"52","DOI":"10.5217\/ir.2024.00168","article-title":"Comparative effectiveness of ustekinumab versus infliximab in the management of perianal fistulizing Crohn\u2019s disease: A retrospective study in China","volume":"24","author":"Chen","year":"2025","journal-title":"Intest. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.cgh.2024.08.032","article-title":"Efficacy and Safety of Upadacitinib for Perianal Fistulizing Crohn\u2019s Disease: A Post Hoc Analysis of 3 Phase 3 Trials","volume":"23","author":"Colombel","year":"2025","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"jjaf099","DOI":"10.1093\/ecco-jcc\/jjaf099","article-title":"The effectiveness of second- and-third-line biologics in perianal Crohn\u2019s disease-a multicenter propensity score-matched study","volume":"19","author":"Shani","year":"2025","journal-title":"J. Crohns Colitis"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1093\/ecco-jcc\/jjae003","article-title":"Efficacy and Safety of Filgotinib for the Treatment of Perianal Fistulising Crohn\u2019s Disease [DIVERGENCE 2]: A Phase 2, Randomised, Placebo-controlled Trial","volume":"18","author":"Reinisch","year":"2024","journal-title":"J. Crohns Colitis"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e925018","DOI":"10.12659\/MSM.925018","article-title":"Infliximab for Crohn\u2019s Disease Patients with Perianal Fistulas: Better Image, Better Life","volume":"26","author":"Hong","year":"2020","journal-title":"Med. Sci. Monit."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1097\/MCG.0000000000001729","article-title":"Rates and Predictors of Long-term Clinical Outcomes in Patients with Perianal Crohn\u2019s Disease on Biologic Therapy","volume":"57","author":"Gubatan","year":"2023","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3994","DOI":"10.1007\/s10620-023-08060-7","article-title":"Superior Efficacy of Infliximab Versus Adalimumab for First-Line Treatment of Crohn\u2019s Perianal Fistulae","volume":"68","author":"Maas","year":"2023","journal-title":"Dig. Dis. Sci."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1136\/gutjnl-2011-300498","article-title":"Interleukin-13 and transforming growth factor beta synergise in the pathogenesis of human intestinal fistulae","volume":"62","author":"Scharl","year":"2013","journal-title":"Gut"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1136\/gutjnl-2023-329964","article-title":"Different levels of healing in inflammatory bowel diseases: Mucosal, histological, transmural, barrier and complete healing","volume":"72","author":"Neurath","year":"2023","journal-title":"Gut"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1136\/gutjnl-2017-315503","article-title":"Developing a core outcome set for fistulising perianal Crohn\u2019s disease","volume":"68","author":"Sahnan","year":"2019","journal-title":"Gut"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0140-6736(00)04017-4","article-title":"Reliable assessment of the effects of treatment on mortality and major morbidity, II: Observational studies","volume":"357","author":"MacMahon","year":"2001","journal-title":"Lancet"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/3\/417\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T15:06:17Z","timestamp":1772636777000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/3\/417"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,4]]},"references-count":27,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["ph19030417"],"URL":"https:\/\/doi.org\/10.3390\/ph19030417","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,4]]}}}